The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments.

"Conflict of interest GB: Consulting fees from Eli Lilly, PharmaMar, AboutEvents; Honoraria from Pharmamar, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dome, Eisai, Istituto Gentili; Support for attending meetings and/or travels from Novartis, Pharmamar, Eli Lilly; Participation on the advisory board from PharmaMar, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dome, Eisai. WT: COI related to the submitted work: Member of the Scientifc Advisory Board of The EHE Foundation; Consulting fees and honoraria: Adaptimmune, Eli Lilly, C4 Therapeutics, Daiichi Sankyo, Deciphera, Adcendo, Ayala Pharmaceuticals, Kowa, Servier, Bayer Pharmaceuticals, Epizyme, Cogent, Medpacto, Foghorn Therapeutics, Amgen, AmMax Bio, Boehringer Ingelheim, BioAtla, Inhibrx, PharmaEssentia, Avacta, Ipsen, Sonata, Curadev, Nuvation Bio, Abbisko; Advisory roles: Certis Oncology – stock ownership, Atropos Therapeutics, co-founder, stock ownership, Innova Therapeutics, Osteosarcoma Institute. RJ: COI related to the submitted work: Member of the Scientific Advisory Board of the EHE Rare Cancer Charity UK; Receipt of grants/research support: MSD, GSK; Receipt of consultation fees: Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks, SynOx, Tracon, Up to Date. SS: COI related to the submitted work: Member of the Scientifc Advisory Board of The EHE Foundation and EHE Rare Cancer Charity UK; Consulting fees and honoraria, or advisory role: Aadi, Astex Pharmaceuticals, Bavarian Nordic, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Deciphera, Epizyme, Gentili, GSK, Agenus, Ikena, MaxiVAX, Novartis, PharmaMar, Pharma Essentia, Rain Therapeutics, Servier. Support for attending meetings and/or travel Pharmamar; Institutional financial interests: Advenchen, Bayer, Blueprint, Daiichi Sankyo, Deciphera, Epizyme, Eli Lilly, GSK, Hutchinson, Inhibrx, Karyopharm, Novartis, PharmaMar, Rain Therapeutics, SpringWorks; unpaid Member of the Scientific Advisory Board of the Chordoma Foundation, Member of the Scientific Advisory Board of the Desmoid Foundation, Member of the Scientific Advisory Board of the Leiomyosarcoma Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article."